Ars Pharmaceuticals Sees Neffy Prescriptions Triple and Revenue Double in Q1
Ars Pharmaceuticals tripled neffy prescription volumes year-over-year and more than doubled related revenue in Q1. The company is nearing CVS Caremark approval for removing prior authorizations by July 1, and extends coverage through a $199 automated conversion process across 90% of pharmacies to support a summer back-to-school surge.
1. CVS Caremark Approval Process
The company is finalizing its proposal with CVS Caremark to remove prior authorization requirements by July 1, which would grant unrestricted access to a significant portion of covered lives. Eric Karas highlighted that marketing initiatives and field force efforts are aligned to maximize uptake once approvals are secured.
2. Surge in Prescriptions and Revenue Growth
Neffy prescriptions increased threefold year-over-year in Q1, driving more than a twofold rise in revenue. Over 28,000 physicians have prescribed the product, with expanding penetration across both high- and lower-decile accounts reflecting broader market adoption.
3. Summer Demand and Automated Claim Conversion
Management anticipates a back-to-school surge in refill prescriptions this summer, supported by a streamlined prescribing process. An automated conversion mechanism now converts 90% of denied claims to a $199 cash price at the pharmacy level, aiming to reduce abandonment rates and boost script volumes into 2027.